Senores Pharmaceuticals Limited reported strong financial and operational performance for the fourth quarter and full year ended March 31, 2026, reflecting sustained growth across regulated markets, emerging markets, and branded generics businesses. The research driven pharmaceutical company announced its audited financial results highlighting significant expansion in revenues, profitability, and